Multivariate analysis of prognostic factors for OS
| Characteristic . | Lugano stage I/II . | Lugano stage IV . | Total . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | |
| Age, y | |||||||||
| ≤ 60 vs > 60 | .260 | 1.917 | 0.618-5.940 | .883 | 1.116 | 0.259-4.811 | .165 | 1.823 | 0.781-4.257 |
| Sex | |||||||||
| Male vs female | .871 | 0.938 | 0.433-2.032 | .348 | 0.620 | 0.228-1.683 | .550 | 0.836 | 0.466-1.502 |
| Performance status | |||||||||
| ECOG < 2 vs ≥ 2 | .206 | 2.969 | 0.549-16.048 | .514 | 1.572 | 0.405-6.107 | .178 | 1.983 | 0.732-5.375 |
| Serum LDH level | |||||||||
| Normal vs increased | .412 | 1.633 | 0.507-5.261 | .970 | 1.033 | 0.190-5.610 | .666 | 1.238 | 0.469-3.266 |
| B symptoms | |||||||||
| Absent vs present | .499 | 1.365 | 0.553-3.366 | .397 | 0.573 | 0.158-2.078 | .466 | 1.281 | 0.659-2.492 |
| No. of extranodal involvements | |||||||||
| < 2 vs ≥ 2 | .795 | 0.817 | 0.178-3.761 | .933 | 0.932 | 0.183-4.749 | .719 | 0.827 | 0.294-2.327 |
| Lugano stage | |||||||||
| I/II vs IV | .932 | 1.050 | 0.345-3.200 | ||||||
| IPI | |||||||||
| L vs LI vs HI vs H | .976 | 1.022 | 0.252-4.140 | .169 | 3.271 | 0.605-17.688 | .330 | 1.640 | 0.607-4.431 |
| Bone marrow | |||||||||
| Normal vs invasive | .514 | 2.130 | 0.220-20.615 | .090 | 0.340 | 0.098-1.182 | .392 | 0.639 | 0.229-1.783 |
| Treatment | |||||||||
| Surgery/chemotherapy vs chemotherapy | .001 | 3.963 | 1.772-8.865 | .667 | 0.761 | 0.220-2.636 | .002 | 2.845 | 1.453-5.568 |
| Chemotherapy regimen | |||||||||
| R-CHOP vs CHOP | .340 | 0.692 | 0.325-1.475 | .212 | 1.853 | 0.704-4.881 | .968 | 1.012 | 0.564-1.815 |
| Characteristic . | Lugano stage I/II . | Lugano stage IV . | Total . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | |
| Age, y | |||||||||
| ≤ 60 vs > 60 | .260 | 1.917 | 0.618-5.940 | .883 | 1.116 | 0.259-4.811 | .165 | 1.823 | 0.781-4.257 |
| Sex | |||||||||
| Male vs female | .871 | 0.938 | 0.433-2.032 | .348 | 0.620 | 0.228-1.683 | .550 | 0.836 | 0.466-1.502 |
| Performance status | |||||||||
| ECOG < 2 vs ≥ 2 | .206 | 2.969 | 0.549-16.048 | .514 | 1.572 | 0.405-6.107 | .178 | 1.983 | 0.732-5.375 |
| Serum LDH level | |||||||||
| Normal vs increased | .412 | 1.633 | 0.507-5.261 | .970 | 1.033 | 0.190-5.610 | .666 | 1.238 | 0.469-3.266 |
| B symptoms | |||||||||
| Absent vs present | .499 | 1.365 | 0.553-3.366 | .397 | 0.573 | 0.158-2.078 | .466 | 1.281 | 0.659-2.492 |
| No. of extranodal involvements | |||||||||
| < 2 vs ≥ 2 | .795 | 0.817 | 0.178-3.761 | .933 | 0.932 | 0.183-4.749 | .719 | 0.827 | 0.294-2.327 |
| Lugano stage | |||||||||
| I/II vs IV | .932 | 1.050 | 0.345-3.200 | ||||||
| IPI | |||||||||
| L vs LI vs HI vs H | .976 | 1.022 | 0.252-4.140 | .169 | 3.271 | 0.605-17.688 | .330 | 1.640 | 0.607-4.431 |
| Bone marrow | |||||||||
| Normal vs invasive | .514 | 2.130 | 0.220-20.615 | .090 | 0.340 | 0.098-1.182 | .392 | 0.639 | 0.229-1.783 |
| Treatment | |||||||||
| Surgery/chemotherapy vs chemotherapy | .001 | 3.963 | 1.772-8.865 | .667 | 0.761 | 0.220-2.636 | .002 | 2.845 | 1.453-5.568 |
| Chemotherapy regimen | |||||||||
| R-CHOP vs CHOP | .340 | 0.692 | 0.325-1.475 | .212 | 1.853 | 0.704-4.881 | .968 | 1.012 | 0.564-1.815 |
CI indicates confidence interval for hazard ratio; LDH, lactate dehydrogenase; L, low; LI, low to intermediate; HI, high to intermediate; and H, high.